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Aims Establishing biochemical markers of pre-hypertension and early hypertension could help earlier diagnostics and thera-
peutic intervention. We assess dynamics of junctional adhesion molecule-A (JAM-A) expression in rat models of
hypertension and test whether JAM-A expression could be driven by angiotensin (ANG) II and whether JAM-A con-
tributes to the progression of hypertension. We also compare JAM-A expression in normo- and hypertensive
humans.
Methods
and results
In pre-hypertensive and spontaneously hypertensive rats (SHRs), JAM-A protein was overexpressed in the brain-
stem microvasculature, lung, liver, kidney, spleen, and heart. JAM-A upregulation at early and late stages was even
greater in the stroke-prone SHR. However, JAM-A was not upregulated in leucocytes and platelets of SHRs. In
Goldblatt 2K-1C hypertensive rats, JAM-A expression was augmented before any increase in blood pressure,
and similarly JAM-A upregulation preceded hypertension caused by peripheral and central ANG II infusions. In
SHRs, ANG II type 1 (AT1) receptor antagonism reduced JAM-A expression, but the vasodilator hydralazine did
not. Body-wide downregulation of JAM-A with Vivo-morpholinos in juvenile SHRs delayed the progression of
hypertension. In the human saphenous vein, JAM-A mRNA was elevated in hypertensive patients with untreated
hypertension compared with normotensive patients but reduced in patients treated with renin–angiotensin
system antagonists.
Conclusion Body-wide upregulation of JAM-A in genetic and induced models of hypertension in the rat precedes the stable ele-
vation of arterial pressure. JAM-A upregulation may be triggered by AT1 receptor-mediated signalling. An association
of JAM-A with hypertension and sensitivity to blockers of ANG II signalling were also evident in humans. We suggest
a prognostic and possibly a pathogenic role of JAM-A in arterial hypertension.
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1. Introduction
In 2003, ‘pre-hypertension’ was officially recognized as a transitional
step to the fully developed disease,1 but what happens during this
initial period is not clear. Moreover, the diagnosis of pre-hypertension
rests exclusively on the detection of blood pressure over a certain
range at rest (systolic pressure .120 and ,140 mmHg), rather than
on a biochemical marker. Such a marker could provide an earlier,
more reliable, and accurate prognostic indicator for essential hyperten-
sion. Subtle pathological changes taking place throughout the body in
pre-hypertension may form harmful positive feedback loops. For
example, activated lymphocytes could cause vascular inflammation
resulting in further activation of the immune system, tissue damage,
and eventually in hypertension.2–4 Junctional adhesion molecule-A
(JAM-A), otherwise known as the F11 receptor or JAM-1,5–7 belongs
to the immunoglobulin superfamily. A transmembrane variant of
JAM-A is expressed by endothelial cells, leucocytes, and platelets, but
an isoform lacking the transmembrane domain also exists as a soluble
protein in plasma.8 In the endothelium and epithelium, JAM-A localized
to cell–cell contacts is known to be involved in leucocyte/platelet/endo-
thelial cell interactions.9,10 We previously found an increased level of
JAM-A mRNA in the brainstem nucleus tractus solitarii (NTS—a key
autonomic control centre) of the spontaneously hypertensive rat
(SHR)11 in adult but also in young pre-hypertensive SHRs, indicating
that it was unlikely to be a reaction to the pressure elevation. Local
adenoviral overexpression of JAM-A in the NTS of normotensive rats
resulted in a transient increase in blood pressure.11 Since then, poly-
morphisms in JAM-A gene have been associated with human hyperten-
sion in a Hong Kong Chinese population,12 suggesting that observations
in SHRs are likely to be relevant to human hypertension. An elevated
level of the soluble form of JAM-A was found in hypertensive patients.13
We hypothesized that the upregulation of JAM-A might be a biochem-
ical marker of developing hypertension. A number of outstanding ques-
tions need to be addressed to support this notion. First, from previous
studies,11 it was not known to what extent changes in JAM-A mRNA
manifest themselves at the protein level. It was unknown whether
JAM-A upregulation observed in the SHR is specific only to this model
or whether it is also characteristic of other animal models of hyperten-
sion (i.e. non-genetically pre-programmed) and human patients. We also
wished to determine whether JAM-A upregulation is evident outside of
the central nervous system and to what extent. Factors triggering JAM-A
upregulation remained unknown and its possible involvement in the
pathogenesis of hypertension required further investigation.
The objectives of the present study were three-fold. First, we have
assessed JAM-A expression at the protein and mRNA level in a range
of commonly used rat models of hypertension. JAM-A expression was
also studied in tissues obtained from patients undergoing coronary
artery bypass surgery (CABG) with normal and elevated blood
pressure. Secondly, we tested the hypothesis that JAM-A upregulation
could be a response to an increase in the activity of an angiotensin
(ANG) II type 1 (AT1) receptor signalling cascade, a characteristic
feature of experimental and clinical hypertension. Finally, we tested
whether a genetic antagonism of JAM-A in SHRs would have any
effect on the onset of hypertension in this model.
2. Methods
An expanded ‘Methods’ section is available in the Supplementary material
online.
2.1 Animal studies
Animal experiments were carried out in accordance with the UK Animals
(Scientific Procedures) Act 1986, consistent with the Guide for the Care
and Use of Laboratory Animals published by the US National Institutes of
Health (NIH Publication, 8th Edition, 2011) and approved by the Univer-
sity of Bristol Ethical Review Group (UB/05/035). The numbers of animals
used in individual experiments are provided in the Supplementary material
online, Table S1, and are also indicated on the graphs.
Following the procedures, animals were anaesthetized using 4–5% iso-
flurane inhalation anaesthesia. Adequate anaesthesia was assured by the
absence of reflexes prior to rapid cervical dislocation and tissues pro-
cessed for real-time RT–PCR, immunohistochemistry, and western blot
analyses of JAM-A (see Supplementary material online for details).
For the generation of the Goldblatt 2K-1C renovascular hypertension
model, male Wistar rats were anaesthetized by intramuscular injection
of a mixture of ketamine (75 mg/kg) and medetomidine (5 mg/kg). The ad-
equacy of anaesthesia was determined by the loss of a pedal withdrawal
reflex. The left renal artery was then partially obstructed with a silver
clip, followed by implantation of a radio-transmitter into the abdominal
aorta for telemetric measurement of arterial blood pressure. The renal
arteries of control rats were not clipped but were exposed.
To establish ANG II-induced hypertension, 7 days after the implantation
of a radio-transmitter into the abdominal aorta, male Wistar rats were
implanted with an ANG II-containing Alzet osmotic pumps subcutaneous-
ly, which delivered at a rate of 200 or 50 ng/kg/min. In a separate group,
Wistar rats were subcutaneously implanted with osmotic pumps, for
intracisternal delivery (5 ng/kg/min). All control rats were infused with
0.9% saline.
To assess the role of ANG II in JAM-A upregulation, 12- to 15-week-old
male SHRs were orally administered losartan at 30 mg/kg/day or hydrala-
zine at 50 mg/kg/day for 4 weeks in drinking water. The doses were cal-
culated and adjusted based on the rate of water consumption which
was monitored and therefore the cited doses are approximations. The
control rats were given drinking water. The tail arterial systolic blood
pressure was determined with tail-cuff sphygmomanometer (IITC Life
Science Inc.) before (week 0) and after 4 weeks of losartan or hydralazine
administration.
2.2 Experiments in the rat brain endothelial
cell line
The rat brain endothelial (RBE4) cell line was maintained with a-MEM/
Ham’s F-10 nutrient mixture (1:1). They were treated with ANG II,
followed by real-time RT–PCR analysis of JAM-A mRNA. In some experi-
ments, RBE4 cells were treated with an AT1 receptor blocker losartan
(1025 M). Control cells were treated with vehicle only.
2.3 JAM-A expression in the human saphenous
vein
Anonymized surplus small fragments of the human saphenous veins were
obtained on the completion of CABG surgery carried out at the Bristol
Heart Institute, from normotensive patients (n ¼ 4), hypertensive patients
without medication (n ¼ 4), and hypertensive patients (n ¼ 15) pre-
scribed with angiotensin-converting enzyme (ACE)-inhibitor and/or
ANG II receptor blocker. Protocols were approved by the local Ethics
Committee and the consent of patients was obtained. JAM-A expression
in the samples of the veins was assessed using real-time RT–PCR.
2.4 Fluorescence-activated cell sorting analysis
of JAM-A expression on leucocytes and
platelets
Blood was collected from the hearts of three euthanized adult, male
Wistar rats and three SHRs. Staining performed with Alexa Fluor 700
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(AF700)-conjugated mouse anti-rat CD4 (AbD Serotec), Phycoerythrin
(PE)-conjugated mouse anti-rat CD54 (ICAM-1) (BD Pharmingen), and
goat anti-rat JAM-A (Santa Cruz) antibodies. Erythrocytes were lysed
using Pharm Lyse (BD Biosciences). The secondary CyTM5-conjugated
Donkey anti-Goat IgG (Jackson ImmnuoResearch) antibody was used
for JAM-A staining. All samples were tested in duplicate. The leucocyte
population was identified by its scatter properties (the parent population).
Platelets were isolated by centrifugation after dilution of lysed blood 1:1
by HEPES-Tyrode buffer to create a platelet-rich plasma layer which
was used for fluorescence-activated cell sorting (FACS). Five thousand
to 10 000 gated events were recorded for each sample. The geometric
mean (average fluorescence of the population) and the percentage of
parent population for the positive and negative groups were calculated
using FlowJo V7.6 (TreeStar Inc.).
2.5 Downregulation of JAM-A with morpholino
in SHRs
Morpholinos are synthetic oligonucleotide-like molecules which induce
gene knockdown by forming stable complexes with the target mRNA.
We have used a specially modified ‘Vivo-morpholinos’ which contain a
unique delivery element. Vivo-morpholino targeting JAM-A molecule
(5′-GTGCCCATTACAGTTTCAATCCCGA-3′) was complementary to
the 5′ region of JAM-A (accession no: BC065309), including the start
codon. As a control, we used Vivo-morpholino oligo (5′-CCTCT
TACCTCAGTTACAATTTATA-3′) which has no known rodent RNA
targets. Both oligos were purchased from Gene Tools LLC (Philomath,
OR, USA) and maintained in sterile saline according to the manufacturer’s
instructions. Four-week-old SHRs (63+ 2 g) were used. Systolic blood
pressure was measured using tail cuff (see Supplementary material
online for details) and anti-JAM-A or control morpholinos were adminis-
tered via the tail vein. Two additional injections were made 5 and 10 days
later (three injections in total, total dose 20 mg/kg), while systolic blood
pressure was monitored weekly until 7 weeks of age. After that, SHRs
were implanted with radiotelemetry transmitters and their level of
blood pressure was assessed 10 days later. Tissues were extracted
and processed for western blotting to demonstrate JAM-A knockdown.
2.6 Data analysis
The data were assessed by analysis of variance (ANOVA) and/or a t-test
where applicable using SPSS software package. Differences between
groups were considered significant at P, 0.05. The data are presented
as mean+ SEM.
3. Results
3.1 Upregulation of JAM-A protein in
genetically pre-programmed hypertension
in SHRs and stroke-prone SHRs
Previously we reported11 the upregulation of JAM-A mRNA in the
NTS of SHRs. Here, we confirmed that the JAM-A mRNA level is
increased in the NTS of both young and mature SHRs and that in
stroke-prone SHRs (SHRSP), which has a more severe hypertensive
phenotype,14 the JAM-A mRNA level was significantly higher than
the SHRs (Figure 1A).
Immunofluorescence analysis revealed that JAM-A protein was
increased in NTS, rostral ventro-lateral medulla (RVLM), and hypo-
thalamic paraventricular nucleus (PVN) of SHRs compared with the
Wistar-Kyoto Rat (WKY) and that levels in SHRSP exceeded those
in the SHR (Figure 1B and C ). For example, in NTS, JAM-A immuno-
fluorescence intensity in mature WKY was 148+9 U/section (n ¼ 6),
while in mature SHRs, it was 433+ 29 U/section (n ¼ 6, P, 0.05 vs.
WKY, ANOVA). In SHRSP, levels increased further to 720+ 45 U/
section (n ¼ 4, P, 0.01 vs. WKY, P, 0.05 vs. SHRs, ANOVA). Inter-
estingly, in pre-hypertensive 3-week-old SHRs, JAM-A levels in NTS,
RVLM, and PVN were much higher than in age-matched WKY rats
(Figure 1B and C ). JAM-A protein was upregulated throughout the
brain including areas not usually involved in autonomic control, such
as the hippocampus and the eighth cerebellar lobule (see Supplemen-
tary material online, Figure S1). Moreover, western blotting showed
JAM-A upregulation in isolated brainstem blood vessels, lung, liver,
kidney, spleen, and heart of SHRs, SHRSP, and young SHRs
(Figure 1D; see Supplementary material online, Figure S2).
Since JAM-A is also expressed on leucocytes and platelets, we
tested whether this upregulation can also be detected in these cells.
FACS has revealed no differences between blood of mature WKY
and SHRs in terms of the numbers of optically detectable leucocytes
(data not shown). SHRs and WKY had a similar frequency of JAM
cvc-A-positive leucocytes within the CD4+ population (P ¼ 0.64),
while there was a slight reduction in the frequency of JAM-A-positive
CD54+ cells (from 29.8+4.5 to 19.9+1.4, P ¼ 0.02; Figure 1E) in
the SHR. Consistently, the level of fluorescence (estimated from
the geometric mean) in SHR CD54+ cells was also significantly
reduced (2453.5+194.0 to 1490+102.3 U, P ¼ 0.01). There was
no significant difference in JAM-A expression on platelets (data not
shown).
3.2 Upregulation of JAM-A in renovascular
hypertension
In a non-genetic Goldblatt 2K-1C-induced hypertension, a significant
elevation in 24 h mean arterial pressure (MAP) was observed after
2 weeks of clipping and then rose further to plateau at week 5
(Figure 2A) as we reported previously.15 After 1 week, when MAP
had not yet elevated, JAM-A was upregulated in the brain including
NTS, RVLM, and PVN (Figure 2B; see Supplementary material
online, Figure S3A–C). The JAM-A level peaked at week 3 and did
not increase further, despite the continued elevation in MAP
(Figure 2A and B; see Supplementary material online, Figure S3A–C).
Upregulation of JAM-A mRNA in NTS was detected as early as
week 1 (Figure 2C), which was consistent with western blot data
showing the elevation of JAM-A in all tested tissues (Figure 2D; see
Supplementary material online, Figure S4).
3.3 Upregulation of JAM-A in hypertension
induced by subcutaneous ANG II infusion
At a rate of 50 ng/kg/min, ANG II sc did not increase 24 h MAP in
Wistar rats until the 10th day of infusion (Figure 3A). Nevertheless,
this dose upregulated JAM-A protein in the brain microvasculature
(NTS, RVLM, and PVN; see Supplementary material online,
Figure S5A, B, D and E) by day 5. The level of JAM-A increased
further by day 10 by which time the MAP became significantly differ-
ent from the saline-treated group (Figure 3A and B; see Supplementary
material online, Figures S5A through D and S6). Early upregulation
of JAM-A at the mRNA level was also confirmed in the NTS
(by 1.60+0.07-fold at day 5 and by 2.00+ 0.09-fold at day 10 of
ANG II infusion; Figure 3B). Western blot revealed body-wide
upregulation of JAM-A (see Supplementary material online,
Figures S5C and S6).
ANG II infused at a higher rate (200 ng/kg/min sc) significantly
increased MAP by day 4 and pressure continued rising until day 10
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(Figure 3C). In these animals, JAM-A protein was dramatically upregu-
lated by day 5 but in contrast to MAP, no further significant increase
occurred after day 5 (see Supplementary material online, Figures S5F,
S7A–D, and S8). A similar pattern was evident at the mRNA level
(Figure 3D).
3.4 Central infusion of ANG II upregulates
JAM-A
Intracerebroventricular infusion of ANG II at 5 ng/kg/min did not sig-
nificantly increase MAP of Wistar rats until day 10 (Figure 3E). Never-
theless, after 5 days of infusion, JAM-A mRNA in the NTS was
elevated by 1.37+0.07-fold (n ¼ 4, P, 0.05 vs. saline control,
ANOVA) and it further increased by 1.80+ 0.09-fold by day 10
(n ¼ 4, P, 0.01 vs. control, P, 0.05 vs. day 5, ANOVA; Figure 3F).
This pattern of JAM-A upregulation was also evident in RVLM and
PVN (see Supplementary material online, Figure S9A and B).
Western blotting confirmed body-wide JAM-A upregulation already
at days 5 and 10 of ANG II icv infusion (see Supplementary material
online, Figure S5G).
3.5 JAM-A expression in SHRs treated with
losartan or hydralazine
We tested how a reduction in pressure in SHRs may impact on the
level of JAM-A. In SHRs, tail arterial systolic pressure was significantly
reduced (n ¼ 8, P, 0.01, ANOVA) by oral administration of losartan
(30 mg/kg/day) for 4 weeks (Figure 4A). This was accompanied by a
downregulation of JAM-A mRNA in RVLM, PVN, and NTS (see Sup-
plementary material online, Figure S10A–C) and a body-wide reduc-
tion in the high JAM-A protein characteristic of the SHR (Figure 4B).
To differentiate between the effect of blocking AT1 receptors vs. low-
ering arterial pressure, hydralazine was infused (50 mg/kg/day for 4
weeks). It significantly decreased systolic pressure in SHRs
(Figure 4C) but did not change JAM-A protein in any of the tested
tissues (Figure 4D) or JAM-A mRNA levels in RVLM, PVN, and NTS
(see Supplementary material online, Figure S10D–F).
Figure 1 Overexpressed JAM-A is associated with genetically pre-programmed hypertension in the SHR and SHRSP. (A) JAM-A mRNA in NTS of
young SHRs (Y-SHR, pre-hypertensive), SHRs (adult and hypertensive), SHRSP, and age-matched normotensive WKY rats. *P, 0.05 and **P, 0.01
vs. WKY rats. #P, 0.05 vs. young WKY(Y-WKY) rats. ‡P, 0.05 vs. SHRs. (B) Immunofluorescence intensity analysis of JAM-A expression in NTS,
RVLM, and PVN from same rat groups as in (A). *P, 0.05 and **P, 0.01 vs. WKY rats. #P, 0.05 vs. young WKY rats. ‡P, 0.05 vs. SHRs. (C) Rep-
resentative confocal images of JAM-A in NTS from same rat groups as in (A). (D) Western blots of JAM-A protein (35 kDa band) in isolated tissues
from same rat groups as in (A) with pan-cadherin as a membrane protein loading control. (E) Representative FACS charts from a WKY and SHRs to
illustrate a slight reduction in CD54+/JAM-A-positive population of leucocytes in SHRs.
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3.6 JAM-A is upregulated in hypertensive
human patients
In veins of patients without a history of hypertension but diagnosed as
hypertensive upon admission (blood pressure .150/100 mmHg, n ¼
4), JAM-A mRNA was upregulated by 4.86+0.55-fold (Figure 4E)
compared with normotensive patients (blood pressure ,140/
90 mmHg, n ¼ 4). In veins from hypertensive patients treated with
either an ACE-inhibitor or an ANG II receptor blocker or their com-
binations with other anti-hypertensive agents (n ¼ 15), the JAM-A
mRNA level was higher than in normotensive subjects but lower
than in untreated patients (Figure 4E; see Supplementary material
online, Table S2).
3.7 ANG II upregulates JAM-A in vitro
We hypothesized that elevated renin–angiotensin system (RAS) activ-
ity could be one of the factors responsible for JAM-A upregulation.
This was investigated in vitro using the RBE4 rat brain endothelial
cell line. JAM-A mRNA in RBE4 cells was elevated by ANG II in a
concentration-dependent manner (1028–1026 M) for 24 h (Figure 5A).
Increased expression of JAM-A became apparent after 8 h of ANG II
treatment (Figure 5B). Pre-treatment with losartan (1025 M) almost
completely prevented the stimulatory effect of ANG II (Figure 5C).
3.8 Morpholino-induced JAM-A knockdown
delays the progression of hypertension in
the SHR
The early upregulation of JAM-A in all the rat models of hypertension
tested here suggested that it could contribute to the establishment of
the pathological level of blood pressure. To attenuate the expression
of JAM-A in the SHR, we used a specially formulated ‘vivo’ morpholino
which was administered to young SHRs during the critical period
between 4 and 8 weeks of age when hypertension develops. The pro-
gression of hypertension in SHRs treated with morpholinos was consist-
ently and significantly attenuated as evidenced using both tail-cuff and
radio-telemetry. In contrast, in animals treated with the control mor-
pholino, blood pressure increased to the levels characteristic of an un-
treated SHR (Figure 6; see Supplementary material online, Figure S11).
The effect of JAM-A targeting morpholino was confirmed by western
blotting showing reduced JAM-A protein (see Supplementary material
online, Figure S12). Finally, we tested the level of blood pressure in
JAM-A knockout mice16 but found that it was comparable to wild-type
littermates, which is probably due to compensation (data not shown).
4. Discussion
This study was based on the previous evidence for JAM-A mRNA
upregulation in the brainstem of SHRs.11 Here, we have confirmed
Figure 2 JAM-A is overexpressed in a Goldblatt (GB) 2K-IC renovascular hypertensive rat model. (A) Time course of 24 h MAP of Wistar rats after
clipping and sham-operated control rats (n ¼ 12 per time point). *P, 0.05 and **P, 0.01 vs. control. #P, 0.05 vs. week 3. (B) Immunofluorescence
intensity analysis of the JAM-A level in NTS from Goldblatt 2K-1C and control rats. *P, 0.05 and **P, 0.01 vs. control. #P, 0.05 vs. week 1. Group
‘week 0’ are untreated rats from the same batch. Four animals were processed for immunofluorescence, real-time PCR, and western blotting from
each group at 1-, 3-, and 6-week post-renal artery clipping. (C) JAM-A mRNA in NTS of Wistar rats of the Goldblatt 2K-1C model and control rats.
*P, 0.05 and **P, 0.01 vs. control. #P, 0.05 vs. week 1. (D) Western blots of JAM-A protein in isolated tissues of Goldblatt 2K-1C control rats.
Lanes 2 and 3 and 4–6 were run on the same gels.
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these observations at the mRNA level, extended them to the protein
level, and found that JAM-A upregulation in this genetic model of
hypertension is not selective for any particular part of the brain and
is detectable throughout the whole body. This includes organs
clearly implicated in blood pressure/volume regulation such as the
kidneys but also others, such as the liver. NTS, PVN, and RVLM
were specifically picked up for the JAM-A level measurement as
they play major roles in the neuro-hormonal regulation of blood pres-
sure. Hence, the expression of JAM-A protein seems to be increased
in all endothelial cells in the SHR and, consistent with our previous
data, is already evident in young, pre-hypertensive animals, indicating
that it is not secondary to the hypertension. Mature SHRs had the
same relative level of JAM-A protein as young SHRs, while the strong-
ly hypertensive phenotype of SHRSP was associated with the greatest
levels of JAM-A supporting an association between this protein and
the severity of hypertension. We acknowledge that in tissues such
as kidneys or lung part of JAM-A protein could include a contribution
from epithelial cells, which are known to also express this protein17,18;
however, brain microvessels were specifically purified and we did not
notice any clear staining outside of blood vessels, indicating that these
measurements only reflect changes in the endothelium. In addition,
the non-vascular myocardium is also devoid of JAM-A (Professor
E. Dejana, Institute of Molecular Oncology, Milan, personal communi-
cation). Finally, the ability of losartan to regulate JAM-A expression via
AT1 receptors requires that the target cells express this receptor. To
the best of our knowledge, AT1 receptors are not described in the
epithelium of the lung or other organs studied here. Therefore,
changes in JAM-A expression in various tissues reported here may
be expected to reflect expression in the endothelium rather than
epithelium.
We have also found JAM-A upregulation at mRNA and protein
levels in two non-genetic models of hypertension: the 2K-1C and
ANG II infusion (peripheral and central). Consistent with the data
from the pre-hypertensive SHR, JAM-A protein upregulation in both
of these models cannot be secondary to hypertension because
JAM-A levels always increased prior to a significant elevation of
MAP. Moreover, in 2K-1C, once high levels of JAM-A protein were
established at around 3 weeks, it did not significantly rise further
Figure 3 JAM-A expression in Wistar rats is elevated ubiquitously after subcutaneous and intracisternal infusion of ANG II infusion of ANG II. (A)
Time course of 24 h MAP in Wistar rats subcutaneously infused with vehicle (control) and ANG II at 50 ng/kg/min. n ¼ 12, *P, 0.05 vs. saline control
(n ¼ 12). (B) JAM-A mRNA in NTS of Wistar rats subcutaneously infused with ANG II at 50 ng/kg/min. *P, 0.05 and **P, 0.01 vs. saline control.
#P, 0.05 vs. day 5. (C) Time course of 24 h MAP of Wistar rats subcutaneously infused with vehicle (control) or ANG II at 200 ng/kg/min. n ¼ 12,
*P, 0.05 and **P, 0.01 vs. saline control. #P, 0.05 vs. day 5. (D) JAM-A mRNA in NTS of Wistar rats subcutaneously infused with ANG II at
200 ng/kg/min. **P, 0.01 vs. saline control. (E) Time course of 24 h MAP of Wistar rats infused intracisternally with ANG II at a rate of 5 ng/kg/
min. n ¼ 8, *P, 0.05 vs. saline control. (F) JAM-A mRNA in NTS of Wistar rats infused intracisternally with vehicle (control) or ANG II at 5 ng/
kg/min. *P, 0.05 and **P, 0.01 vs. saline control. #P, 0.05 vs. day 5.
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Figure 4 Effect of losartan and hydralazine on JAM-A expression in SHRs (A–D) and JAM-A expression in the human saphenous vein from hyper-
tensive patients (E). (A) Tail arterial systolic blood pressure of SHRs orally administered losartan or drinking water. n ¼ 8, **P, 0.01 vs. vehicle
control. (B) Western blots of JAM-A protein in isolated tissues of SHRs. (C) Tail arterial systolic blood pressure of SHRs orally administered hydra-
lazine or drinking water. n ¼ 8, **P, 0.01 vs. vehicle control. (D) Western blots of JAM-A in isolated tissues of SHRs. n ¼ 4 per group. (E) JAM-A
mRNA in saphenous veins of normotensive patients (n ¼ 4), hypertensive patients without medication (n ¼ 4), and hypertensive patients treated with
ACE-inhibitors and/or AT1 receptor blockers (n ¼ 15). *P, 0.05 and **P, 0.01 vs. normotension. #P, 0.05 vs. hypertension without medication.
See Supplementary material online, Table S2, for further information on the treatments.
Figure 5 ANG II drives JAM-A expression in RBE4 rat brain endothelial cells. (A) JAM-A mRNA in RBE4 cells increases after doses of ANG II from
1026 to 1028 M; no changes were seen following the treatment with vehicle. *P, 0.05 and **P, 0.01 vs. control. #P, 0.05 vs. 1028 M. (B) JAM-A
mRNA in RBE4 cells treated with ANG II at 1027 M for various durations (h). *P, 0.05 and **P, 0.01 vs. vehicle control. (C) JAM-A mRNA in RBE4
cells pre-treated with losartan at 1025 M for 1 h, followed by stimulation with ANG II at 1027 M for 24 h. *P, 0.05 and **P, 0.01 vs. vehicle control.
#P, 0.05 vs. ANG II. Results are mean+ SEM of four duplicates in each group.
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despite a dramatic increase in arterial pressure between 3 and 6
weeks post-clipping. Similarly, in rats infused with 50 ng/kg/min,
ANG II JAM-A expression increased by day 5, yet at the arterial pres-
sure only became marginally different from control by day 10.
Interestingly, even hypertension induced by central infusion of
ANG II is preceded by increased expression of JAM-A, and this is de-
tectable in both central and peripheral blood vessels. It has been re-
cently shown that central ANG II might activate T-lymphocytes
triggering a generalized immune response which possibly acts in a
feed-forward manner to further rise blood pressure.2 JAM-A upregu-
lation could therefore facilitate this mechanism as it is involved in
leucocyte adhesion and transmigration.19 It may also increase platelet
adhesion to the endothelium potentially leading to inflammatory
thrombosis.20 Such effects of JAM-A could facilitate the development
of hypertension, and consistent with this idea, downregulation of
JAM-A in young SHRs with morpholino delayed the usual age-
dependent progression of hypertension. We acknowledge that this
knockdown was not targeted to the endothelium and was body-wide.
Nevertheless, the present results are consistent with the pro-
hypertensive role of a high level of JAM-A as was originally hypothe-
sized.11 The possible pathogenic role of JAM-A-related intracellular
signalling in hypertension requires further investigation.
Several observations from this study suggest that ANG II might be
one of the factors responsible for JAM-A upregulation in hyperten-
sion. First, JAM-A is upregulated by ANG II in vitro in the RBE4
cell line. The effect of ANG II on JAM-A level is concentration-
dependent and can be blocked by losartan. Secondly, when the
SHR is treated with losartan, JAM-A expression is reduced in parallel
with the fall in arterial pressure. This was not due to hypotension
because hydralazine, which decreased blood pressure similarly to
losartan, did not affect JAM-A levels. Thirdly, the hypertensive
patients in the cohort treated with ACE-inhibitors and/or AT1 re-
ceptor blockers had lower expression of JAM-A in the saphenous
vein compared with those diagnosed hypertension but not treated
with these drugs.
If it is the local tissue RAS which is responsible for the upregulation
of JAM-A, there should not necessarily be a correlation between cir-
culating levels of renin or ANG II with expression of JAM-A. The
present study demonstrated that central infusion of ANG II leads to
an increase in JAM-A levels throughout the body. This suggests that
centrally induced hypertension can trigger the activation of local
RAS in the peripheral tissues, or alternatively, JAM-A upregulates in
response to an increase in sympathetic activity triggered by central
ANG II. There is a consensus that ANG II may trigger vascular in-
flammation by inducing oxidative stress and upregulation of pro-
inflammatory transcription factors such as nuclear factor kappa B
(NF-kB). These in turn regulate expression of inflammatory mediators
(e.g. C-reactive protein, chemokines, and adhesion molecules) which
leads to endothelial dysfunction and vascular injury characteristic of
sustained hypertension.21–23 Intriguingly, a molecule with somewhat
overlapping functions, the intercellular adhesion molecule-1
(ICAM-1), can be upregulated by ANG II in the brain endothelium
in vitro via an AT1 receptor/NF-kB pathway.
24 The structure of the
JAM-A gene is quite complex, but its promoter also contains a con-
sensus for NF-kB, providing a converging pathway for ANG II modu-
lation.25 Moreover, endothelial ICAM, JAM-A, and platelet endothelial
cell adhesion molecule were demonstrated to act together to facili-
tate neutrophil transmigration through the activated endothelium26
and it is possible that they represent a cascade pathologically activated
in pre-hypertension and the early stages of hypertension. At these
stages, the upregulation of JAM-A could facilitate vascular inflamma-
tion resulting from T-lymphocyte activation2,3 and help to form the
vicious positive feedback circle leading to hypertension. Interestingly,
no upregulation of JAM-A was detected in leucocytes or platelets by
FACS analysis, suggesting that the phenomenon is driven by a specific
signalling cascade. Since leucocytes and platelets do not express AT1
receptors, it could be the reason why these cell types are not a part of
the generalized JAM-A upregulation, which is driven by ANG II as our
data suggest.
In summary, the present study demonstrates that body-wide upre-
gulation of JAM-A at mRNA and protein levels occurs in several
widely used rat models of hypertension ‘before’ the arterial pressure
deviates from control. JAM-A also contributes to the establishment of
hypertension in SHRs. Importantly, there is a big increase in JAM-A
mRNA in venous tissue from hypertensive human patients which
can be partially off-set by anti-hypertensive medication involving
blockade of the RAS. The upregulation of JAM-A prior to the onset
of the sustained elevation of MAP suggests that it reflects genetic
or biochemical reorganization which occurs in the pre-hypertensive
state, likely under the influence of subpressor levels of ANG II.
5. Clinical perspective
This study demonstrates that early body-wide upregulation of JAM-A
is a unifying feature of several commonly used rat models of hyperten-
sion. Moreover, a high level of JAM-A is sustained when the hyperten-
sion fully develops. Strong upregulation of the endothelial form of
JAM-A in human patients shown here is consistent with the recent
reports of both an increase in concentration of the soluble isoform
of JAM-A in human hypertension and association of the polymorph-
isms in JAM-A gene with obesity and hypertension in man. Because
JAM-A upregulation precedes sustained elevation of blood pressure,
these observations raise an intriguing possibility of using JAM-A as
an early biochemical marker of the pre-hypertensive state. Moreover,
Figure 6 Effect of anti-JAM-A morpholino on arterial blood pres-
sure in young SHRs. Systolic blood pressure (BP) was assessed using
tail-cuff during weeks 4–7. After that, animals were implanted with
radio-transmitters and their BP was assessed using telemetry 1 week
later (weeks 9–10). Diastolic BP and mean BP were also decreased
according to telemetry (see Supplementary material online, Figure
S12). *P, 0.05 (ANOVA), n ¼ 4–6 rats per data point.
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since real-time PCR requires only minute quantities of tissue,
there might be a possibility to establish a clinically applicable test
for JAM-A expression in biopsy samples from peripheral tissues.
Further studies are needed to establish whether upregulation of the
soluble variant of JAM-A also is detectable in pre-hypertension.
Supplementary material
Supplementary material is available at Cardiovascular Research online.
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